NfL (Commercial assay)
A structural axonal protein released upon neuronal damage, serving as a sensitive marker for neurodegeneration and axonal injury.
Key features and values
- Measures neurofilament light chain levels in serum or cerebrospinal fluid, indicative of axonal damage.
- Reflects neurodegenerative activity, providing insights into disease progression.
- Validated for use in human biofluids, ensuring reliable and reproducible measurements.
- Non-invasive tool for assessing axonal injury, suitable for routine sampling.
- Elevated NfL levels correlate with increased neurodegeneration in conditions such as multiple sclerosis and Alzheimer’s disease.
- Useful for monitoring therapeutic response, with changes in NfL levels reflecting the efficacy of neuroprotective treatments.
- Facilitates research and development of targeted therapies by providing insights into axonal injury mechanisms.
Description
The NfL biomarker assay is designed to quantify neurofilament light chain levels in serum or cerebrospinal fluid, serving as a specific indicator of axonal damage. Neurofilament light chain is a structural protein of neurons, and its release into biofluids reflects neurodegeneration. By measuring NfL, the assay provides a direct assessment of neuronal injury.
This assay has been validated for use in human biofluids, demonstrating its reliability and reproducibility in various clinical and research settings. Elevated NfL levels have been associated with increased neurodegeneration in conditions such as multiple sclerosis and Alzheimer’s disease. The non-invasive nature of the test makes it suitable for routine monitoring of axonal injury and the effectiveness of neuroprotective therapies.
In addition to its clinical applications, the NfL assay serves as a valuable tool in research, facilitating the study of neurodegenerative mechanisms and the development of targeted treatments aimed at modulating axonal injury processes.
